Journal
CANCERS
Volume 13, Issue 16, Pages -Publisher
MDPI
DOI: 10.3390/cancers13163958
Keywords
hepatocellular carcinoma; atezolizumab; bevacizumab; immune checkpoint inhibitor; tumor marker; alpha-fetoprotein; real-world practice; molecular targeted agents
Categories
Funding
- Bristol-Meyers Squibb
- Dainippon Sumitomo Pharma
- TORAY
- Eisai
- Otsuka Pharma
- Mitsubishi Tanabe Pharma
- Daiichi Sankyo
Ask authors/readers for more resources
The study aimed to investigate the early tumor response and safety of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma patients. The results showed that AFP may be useful in assessing early response, and the treatment was safe, including in patients with prior MTA treatments, although adverse events were more frequent in patients with prior treatment.
The aim of this study was to investigate the early tumor response and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma in real-world practice. Forty patients with Child-Pugh class A liver function and eastern cooperative oncology group performance status 0 or 1 were enrolled. The objective response rate (ORR) at six weeks after the start of treatment, changes in alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin, incidence of adverse events (AEs), and changes in albumin-bilirubin (ALBI) score and serum ammonia level, were evaluated. Among 40 patients, 24 had histories of prior molecular targeted agents (MTAs). The ORR was 22.5% based on mRECIST. Multivariate analysis showed that an AFP ratio <1.0 at three weeks (odds ratio 39.2, 95% confidence interval CI 2.37-649.0, p = 0.0103) was the only significant factor for predicting early response. There was no significant difference in the frequency of AEs between patients receiving first-line treatments and others. Fatigue, proteinuria, and ascites were more frequent in patients who experienced prior treatment. No decrease in ALBI score or increase in serum ammonia level was observed. Our study demonstrated that AFP may be useful in assessing early response and that this treatment is safe, including in patients with prior MTA treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available